Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nabumetone
Drug ID BADD_D01511
Description Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.[A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]
Indications and Usage For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code M01AX01
DrugBank ID DB00461
KEGG ID D00425
MeSH ID D000077430
PubChem ID 4409
TTD Drug ID D05CKR
NDC Product Code 63629-2682; 0591-3671; 69367-242; 79739-7077; 0115-1658; 76282-257; 50228-465; 60760-386; 72189-184; 69367-241; 43063-859; 0115-1657; 61919-698; 63629-8510; 71335-1234; 62331-008; 68788-7765; 49706-0681; 61919-668; 63187-307; 50090-0747; 71205-530; 65015-632; 60760-369; 0591-3670; 63629-8506; 55700-840; 71205-030; 71335-1272; 68071-4844; 15370-170; 72189-072; 70934-013; 80425-0054; 73684-100; 70934-847; 73684-101; 79739-7076; 55700-845; 71205-977; 61919-609; 68788-7597; 50090-5294; 68462-358; 53002-6960; 51655-396; 50090-0800; 45865-351; 45865-464; 63629-8508; 60760-387; 68071-5166; 45865-997; 71205-978; 71335-1391; 69097-965; 65977-0082; 63629-7699; 80425-0104; 61919-626; 60760-368; 69097-966; 72789-040; 71335-0531; 45865-111; 63629-8509; 76420-210; 43063-973; 80425-0053; 76282-258; 24196-135; 50090-5386; 68180-142; 63187-484; 63187-378; 43063-972; 60687-630; 80425-0052; 50090-3433; 68180-141; 71335-1559; 68462-359; 50228-466; 79739-7078; 60760-015
Synonyms Nabumetone | Nabumeton | 4-(6-Methoxy-2-naphthyl)-2-butanone | Relifex | Relif | Apo-Nabumetone | ApoNabumetone | Mebutan | Listran | Gen-Nabumetone | Arthraxan | BRL 14777 | Rhoxal-nabumetone | Rhoxal nabumetone | Relafen | Nabucox
Chemical Information
Molecular Formula C15H16O2
CAS Registry Number 42924-53-8
SMILES CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oesophageal ulcer07.04.05.0020.000737%
Oesophagitis07.08.05.0010.000737%
Oliguria20.01.03.0040.001474%Not Available
Pain08.01.08.0040.001105%
Palmar-plantar erythrodysaesthesia syndrome23.07.04.001; 17.02.07.0090.000737%
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005--
Peptic ulcer07.04.07.001--Not Available
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pruritus23.03.12.001--
Pseudoporphyria23.03.01.006--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.000737%Not Available
Rash maculo-papular23.03.13.0040.000737%
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal failure20.01.03.005--Not Available
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages